Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Loughbeg, Co. Cork. Thursday, September 5th, 2019: Hovione is celebrating its 60th Anniversary today in its site in Cork.
Hovione has issued a bond of $50 million US dollars maturing in 2033.
‘One Site Shop’ expands to respond to growing demands
Hovione reported today recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey.
Hovione announced today that in the last year their manufacturing facilities were the object of eight inspections, performed by different Health Authorities.
Hovione announces that it has concluded the sale of all of the share capital of iMAX Diagnostic Imaging limited.
Hovione announced that a new MG2 Tekna Precision Capsule filling unit is now online in its Portugal facilities
A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
Hovione announced today the appointment of Mr. Frédéric Kahn as Vice President Marketing and Sales, as of 1st September, 2017